Apyx Medical Corporation provided earnings guidance for the year ending December 31, 2024. For the year, the company expects Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December 31, 2023. Net loss attributable to stockholders of approximately $26.5 million to $24.3 million, compared to $18.7 million for the year ended December 31, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | 0.00% | +11.89% | -38.93% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.93% | 55.43M | |
-6.16% | 181B | |
+2.78% | 114B | |
-2.78% | 68.29B | |
+5.66% | 52.24B | |
+7.56% | 44.3B | |
+6.67% | 42.73B | |
+25.26% | 32.52B | |
+20.03% | 26.02B | |
-2.83% | 25.91B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024